Ice Lounge Media

Ice Lounge Media

Twitter addresses questions of bias in its image-cropping algorithms, we take a look at Mario Kart Live and the stock market takes a hit after President Trump’s COVID-19 diagnosis. This is your Daily Crunch for October 2, 2020.

The big story: Twitter confronts image-cropping concerns

Last month, (white) PhD student Colin Madland highlighted potential algorithmic bias on Twitter and Zoom — in Twitter’s case, because its automatic image cropping seemed to consistently highlight Madland’s face over that of a Black colleague.

Today, Twitter said it has been looking into the issue: “While our analyses to date haven’t shown racial or gender bias, we recognize that the way we automatically crop photos means there is a potential for harm.”

Does that mean it will stop automatically cropping images? The company said it’s “exploring different options” and added, “We hope that giving people more choices for image cropping and previewing what they’ll look like in the tweet composer may help reduce the risk of harm.”

The tech giants

Nintendo’s new RC Mario Kart looks terrific — Mario Kart Live (with a real-world race car) makes for one hell of an impressive demo.

Tesla delivers 139,300 vehicles in Q3, beating expectations — Tesla’s numbers in the third quarter marked a 43% improvement from the same period last year.

Zynga completes its acquisition of hyper-casual game maker Rollic — CEO Frank Gibeau told me that this represents Zynga’s first move into the world of hyper-casual games.

Startups, funding and venture capital

Elon Musk says an update for SpaceX’s Starship spacecraft development program is coming in 3 weeks —  Starship is a next-generation, fully reusable spacecraft that the company is developing with the aim of replacing all of its launch vehicles.

Paired picks up $1M funding and launches its relationship app for couples — Paired combines audio tips from experts with “fun daily questions and quizzes” that partners answer together.

With $2.7M in fresh funding, Sora hopes to bring virtual high school to the mainstream — Long before the coronavirus, Sora was toying with the idea of live, virtual high school.

Advice and analysis from Extra Crunch

Spain’s startup ecosystem: 9 investors on remote work, green shoots and 2020 trends — While main hubs Madrid and Barcelona bump heads politically, tech ecosystems in each city have been developing with local support.

Which neobanks will rise or fall? — Neobanks have led the $3.6 billion in venture capital funding for consumer fintech startups this year.

Asana’s strong direct listing lights alternative path to public market for SaaS startups — Despite rising cash burn and losses, Wall Street welcomed the productivity company.

Everything else

American stocks drop in wake of president’s COVID-19 diagnosis — The news is weighing heavily on all major American indices, but heaviest on tech shares.

Digital vote-by-mail applications in most states are inaccessible to people with disabilities — According to an audit by Deque, most states don’t actually have an accessible digital application.

The Daily Crunch is TechCrunch’s roundup of our biggest and most important stories. If you’d like to get this delivered to your inbox every day at around 3pm Pacific, you can subscribe here.

Read more

The president of the United States, Donald Trump, tested positive for covid-19 and within 24 hours had received an experimental, cutting-edge antibody treatment not available to other Americans.

In a statement released Friday, the White House said Trump had received “a single 8-gram dose” of the biotech treatment, which belongs to a promising new class of antiviral drugs.

The president “remains fatigued but in good spirits” after getting the emergency infusion, according to White House doctor Sean Conley. “He’s being evaluated by a team of experts, and together we’ll be making recommendations to the president and first lady in regards to best next steps.”

Trump and his wife, who also tested positive, were certain to have access to the best medical care the country can provide, including experimental drugs not available to others.

The White House said the president had received an IV infusion of a cocktail of antibodies manufactured by Regeneron Pharmaceuticals, of Tarrytown, New York. That treatment is essentially a way to mimic a powerful immune response in order to ward off a serious case of covid-19.

Because he is overweight and 74 years old, the president is at higher than average risk for developing a serious case of the disease. And the chance of death for someone like him is not small—it’s at least 5%, about 100 times as great for him as for someone under 30.

Trump’s doctors immediately had to make some tough decisions in deciding what drugs to give him. For one thing, they had to assess medical evidence that’s been consistently clouded by the White House itself and treat a patient who has shown interest in hokum treatments like bleach, second-guessed medical authorities, and even given a bullhorn to a doctor who believes in witchcraft.

The president has “mild symptoms,” according to his chief of staff, Mark Meadows. It usually takes several days before more serious covid-19 symptoms manifest, if they do. As long Trump isn’t in the hospital,  he would be classified as a lower-risk “outpatient.”

For nearly any other American, that would mean being told to wait and see how the symptoms develop, because there aren’t any covid-19 drugs approved for outpatients. Two treatments, blood plasma and the antiviral drug remdesivir, did receive emergency approval, but only for people who are hospitalized.

But Trump isn’t just anyone. So expect his doctors to consider—and maybe get hold of—experimental drugs that have shown promise, even if they have received no approval yet. The same could go for Melania Trump and other members of the inner circle who tested positive.

Drug company analysts at Raymond James early Friday put out a note to clients rating what experimental treatments they thought Trump was “most likely” to get. At the front of their list: the antibody drug manufactured by Regeneron, which is still being studied.

The stock analysts were exactly right. By Friday afternoon, the White House issued a statement saying that the president had already received the treatment.

The antibodies Regeneron makes are similar to those developed by people who catch the virus and survive it. Given in a concentrated dose administered through an intravenous drip, the manufactured antibodies are designed to grab hold of the viral particles and neutralize them.

The expectation for such treatments is that if given early to patients like Trump, they might stop the disease from ever progressing to its most serious stage of pneumonia and death.

Just this week, Regeneron said a study of nearly 300 outpatients showed that the antibody treatment cut down on the amount of virus in patients’ bodies. There were also hints that those who got the drug were less likely to end up in a doctor’s office, making it one of the most exciting new candidate treatments. (A similar antibody is being made and tested by Eli Lilly.)

When contacted by MIT Technology Review early on Friday, Regeneron was not willing to say whether the White House had already asked for doses of its antibody, REGN-COV2. “As a matter of policy, we don’t identify individuals without their consent who have or have not submitted a request,” spokesperson Alexandra Bowie said in an email.

Although Regeneron’s drug is not approved, many companies run “compassionate use” programs that can allow people who are not in their trials to get the treatment in special cases, and that’s apparently exactly what Trump qualified for.

“There is limited product available for compassionate-use requests that are approved under certain exceptional circumstances on a case-by-case basis,” Bowie said. The US Food and Drug Administration would have had to rapidly sign off on Trump’s treatment request too.

Regeneron declined to explain the series of events that led to Trump’s treatment, but a presidential request would not have been easy to turn down. Trump also appears to have a warm relationship with the New York company’s billionaire CEO and cofounder, Leonard Schleifer, who back in March was among a select group of executives brought to the White House for a meeting about how biotech might solve the crisis with drugs or vaccines.

What’s certain is that any company whose drug Trump takes could get a massive boost of publicity, perhaps even from the presidential Twitter feed. Today’s events could also accelerate an emergency approval for Regeneron’s drug, which would make it available to more people.

Another drug doctors will have to consider for Trump is remdesivir, made by Gilead Pharmaceuticals. It’s never been shown to benefit just-diagnosed patients, like Trump, and is approved only for those who are hospitalized. But in the case of a sitting president, doctors might have to judge the risks and benefits differently.

And don’t forget that Trump will have a say in his treatment. That’s a wild card, because he has a pattern of taking medical advice from partisan sources rather than medical ones. For instance, he announced in May that he was taking hydroxychloroquine, an antimalarial then touted by conservative personalities including Rudy Giuliani as a covid-19 cure-all.

His doctor, the military osteopath Sean Conley, later confirmed Trump had taken the pills, even though most health experts say the drug doesn’t prevent infection or cure it.

The same doctor, in a memo, assured the American people that Trump would beat all the medical odds and sail through his bout with the coronavirus. In a short statement, in which he confirmed the diagnosis of the president and the first lady, Conley said, “Rest assured, I expect the president to continue carrying out his duties without disruption while recovering.”

No one can say if that will actually happen. But the fast decision to give Trump the antibody made by Regeneron could be the best shot the president had.

Read more

In November of 2018, a new deep-learning tool went online in the emergency department of the Duke University Health System. Called Sepsis Watch, it was designed to help doctors spot early signs of one of the leading causes of hospital deaths globally.

Sepsis occurs when an infection triggers full-body inflammation and ultimately causes organs to shut down. It can be treated if diagnosed early enough, but that’s a notoriously hard task because its symptoms are easily mistaken for signs of something else.

Sepsis Watch promised to change that. The product of three and a half years of development (which included digitizing health records, analyzing 32 million data points, and designing a simple interface in the form of an iPad app), it scores patients on an hourly basis for their likelihood of developing the condition. It then flags those who are medium or high risk and those who already meet the criteria. Once a doctor confirms the diagnosis, the patients get immediate attention.

In the two years since the tool’s introduction, anecdotal evidence from Duke Health’s hospital managers and clinicians has suggested that Sepsis Watch really works. It has dramatically reduced sepsis-induced patient deaths and is now part of a federally registered clinical trial expected to share its results in 2021.

At first glance, this is an example of a major technical victory. Through careful development and testing, an AI model successfully augmented doctors’ ability to diagnose disease. But a new report from the Data & Society research institute says this is only half the story. The other half is the amount of skilled social labor that the clinicians leading the project needed to perform in order to integrate the tool into their daily workflows. This included not only designing new communication protocols and creating new training materials but also navigating workplace politics and power dynamics.

The case study is an honest reflection of what it really takes for AI tools to succeed in the real world. “It was really complex,” says coauhtor Madeleine Clare Elish, a cultural anthropologist who examines the impact of AI.

Repairing innovation

Innovation is supposed to be disruptive. It shakes up old ways of doing things to achieve better outcomes. But rarely in conversations about technological disruption is there an acknowledgment that disruption is also a form of “breakage.” Existing protocols turn obsolete; social hierarchies get scrambled. Making the innovations work within existing systems requires what Elish and her coauthor Elizabeth Anne Watkins call “repair work.”

During the researchers’ two-year study of Sepsis Watch at Duke Health, they documented numerous examples of this disruption and repair. One major issue was the way the tool challenged the medical world’s deeply ingrained power dynamics between doctors and nurses.

In the early stages of tool design, it became clear that rapid response team (RRT) nurses would need to be the primary users. Though attending physicians are typically in charge of evaluating patients and making sepsis diagnoses, they don’t have time to continuously monitor another app on top of their existing duties in the emergency department. In contrast, the main responsibility of an RRT nurse is to continuously monitor patient well-being and provide extra assistance where needed. Checking the Sepsis Watch app fitted naturally into their workflow.

But here came the challenge. Once the app flagged a patient as high risk, a nurse would need to call the attending physician (known in medical speak as “ED attendings”). Not only did these nurses and attendings often have no prior relationship because they spent their days in entirely different sections of the hospital, but the protocol represented a complete reversal of the typical chain of command in any hospital. “Are you kidding me?” one nurse recalled thinking after learning how things would work. “We are going to call ED attendings?”

But this was indeed the best solution. So the project team went about repairing the “disruption” in various big and small ways. The head nurses hosted informal pizza parties to build excitement and trust about Sepsis Watch among their fellow nurses. They also developed communication tactics to smooth over their calls with the attendings. For example, they decided to make only one call per day to discuss multiple high-risk patients at once, timed for when the physicians were least busy.

On top of that, the project leads began regularly reporting the impact of Sepsis Watch to the clinical leadership. The project team discovered that not every hospital staffer believed sepsis-induced death was a problem at Duke Health. Doctors, especially, who didn’t have a bird’s-eye view of the hospital’s statistics, were far more occupied with the emergencies they were dealing with day to day, like broken bones and severe mental illness. As a result, some found Sepsis Watch a nuisance. But for the clinical leadership, sepsis was a huge priority, and the more they saw Sepsis Watch working, the more they helped grease the gears of the operation.

Changing norms

Elish identifies two main factors that ultimately helped Sepsis Watch succeed. First, the tool was adapted for a hyper-local, hyper-specific context: it was developed for the emergency department at Duke Health and nowhere else. “This really bespoke development was key to the success,” she says. This flies in the face of typical AI norms. 

Second, throughout the development process, the team regularly sought feedback from nurses, doctors, and other staff up and down the hospital hierarchy. This not only made the tool more user friendly but also cultivated a small group of committed staff members to help champion its success. It also made a difference that the project was led by Duke Health’s own clinicians, says Elish, rather than by technologists who had parachuted in from a software company. “If you don’t have an explainable algorithm,” she says, “you need to build trust in other ways.”

These lessons are very familiar to Marzyeh Ghassemi, an incoming assistant professor at MIT who studies machine-learning applications for health care. “All machine-learning systems that are ever intended to be evaluated on or used by humans must have socio-technical constraints at front of mind,” she says. Especially in clinical settings, which are run by human decision makers and involve caring for humans at their most vulnerable, “the constraints that people need to be aware of are really human and logistical constraints,” she adds.

Elish hopes her case study of Sepsis Watch convinces researchers to rethink how to approach medical AI research and AI development at large. So much of the work being done right now focuses on “what AI might be or could do in theory,” she says. “There’s too little information about what actually happens on the ground.” But for AI to live up to its promise, people need to think as much about social integration as technical development.

Her work also raises serious questions. “Responsible AI must require attention to local and specific context,” she says. “My reading and training teaches me you can’t just develop one thing in one place and then roll it out somewhere else.”

“So the challenge is actually to figure how we keep that local specificity while trying to work at scale,” she adds. That’s the next frontier for AI research.

Read more

The square-faced, three-legged alien shoves and jostles to get at the enormous plant taking over its tiny planet. But each bite just makes the forbidden fruit grow bigger. Suddenly the plant’s weight flips the whole sphere upside down and all the little creatures drop into space.

Quick! Reach in and catch one!

Agence, a short interactive VR film from Toronto-based movie studio Transitional Forms, won’t be breaking any box office records. Falling somewhere in the no-man’s-land between movies and video games, it may struggle to find an audience at all. But as the first example of a film that uses reinforcement learning to control its animated characters, it could be a glimpse into the future of filmmaking.

“I am super passionate about artificial intelligence because I believe that AI and movies belong together,” says the film’s director, Pietro Gagliano.

Gagliano previously won the first-ever Emmy for a VR experience in 2015. Now he and producer David Oppenheim, who works at the National Film Board of Canada, are experimenting with a kind of storytelling they call dynamic film. “We see Agence as a sort of silent-era dynamic film,” says Oppenheim. “It’s a beginning, not a blockbuster.”

Agence was debuted at the Venice International Film Festival last month and was released this week to watch/play via Steam, an online video-game platform. The basic plot revolves around a group of creatures and their appetite for a mysterious plant that appears on their planet. Can they control their desire, or will they destabilize the planet and get tipped to their doom? Survivors ascend to another world. After several ascensions, there is a secret ending, says Oppenheim.  

Gagliano and Oppenheim want viewers to have the option of sitting back and watching a story unfold, with the AI characters left to their own devices, or getting involved and changing the action on the fly. There’s a broad spectrum of interactivity, says Gagliano: “A lot of interactive films have decision moments, when you can branch the narrative, but I wanted to create something that let you transform the story at any point.”

A certain degree of interactivity comes from choosing the type of AI that controls each character. You can make some use rule-based AI, which guides the character using simple heuristics—if this happens, then do that. Then you can make others become reinforcement-learning agents trained to seek rewards however they like, such as fighting for a bite of the fruit. Characters that follow rules stick closer to Gagliano’s direction; RL agents inject some chaos.

But you can also lean in. Using VR controls or a game pad, you can grab characters and move them around, plant more giant flowers, and help balance the planet. The characters carry on with their business around you, seeking their rewards as best they can.

The film got some interest in Venice, says Oppenheim: “A lot of people come looking for that mix of story and interactivity. Introducing AI into the mix was something that people responded really well to.”

Gagliano’s mother also likes it. When he showed it to her, she spent the whole time breaking up fights between the creatures. “She was like, ‘You behave! You go back here and you play nicely,’” he says. “That was a storyline I wasn’t expecting.”

But people expecting a game have had a cooler response. “Gamers treat it more as a puzzle,” says Oppenheim. And the short running time and lack of challenge have put off some online reviewers.

Still, the pair see Agence as a work in progress. They want to collaborate with other AI developers to give their characters different desires, which would lead to different stories. In the long run, they think, they could use AI to generate all parts of a film, from character behavior to dialogue to entire environments. It could create surprising, dreamlike experiences for all of us, says Oppenheim. 

Read more

The evidence that the coronavirus spreads through the air has been mounting for months. However, the official guidance from the World Health Organization and Centers for Disease Control is still that droplets are the main route of transmission. In fact, the CDC changed its website last month to acknowledge airborne transmission as a route for covid-19 infections but removed the new guidance just days later, saying it had been posted in error. An official told CNN that it “wasn’t ready to be posted.” All clear?

Back in July, a group of 239 experts sent an open letter to the WHO imploring it to acknowledge airborne transmission. Three months later, the WHO’s guidance has changed subtly but still only suggests airborne transmission plays a limited role. Rather than wait for officialdom to catch up, one of those signatories, Jose-Luis Jimenez, a chemistry professor at the University of Colorado, Boulder, who has studied aerosols for 20 years, decided to go straight to the public with the latest advice on how people can protect themselves and those around them. He convened a group of nine other experts in the field to create this open-access Google Doc offering comprehensive advice on what you need to know about aerosol transmission, from best practices for masks to whether it’s safe to travel by airplane.

We spoke to him about why he created the document, and the response he’s had so far. The conversation has been condensed and lightly edited for clarity.

Why did you create this document?

A lot of people were asking questions, so I thought it made sense to put them in one place. It means you don’t have to keep repeating yourself, and you can tweak the document and improve it over time. We [aerosol transmission experts] were answering so many questions on Twitter and via email. I’ve had several thousand emails and Twitter questions. But the answer is so often the same. Some of the coauthors I found through the WHO open letter, others I found via Twitter, and I proposed to them, “What do you think about putting our research together, so we don’t have to keep repeating ourselves so much?” A few of them said yes, so I set it up, put in some questions, and then others starting adding theirs in too. When we saw it was useful, we made it public. We update the document all the time. We’re effectively having to be a little WHO or CDC. We’re saying the things that they should be saying. This is frustrating, but it’s the situation we find ourselves in. These organizations have been flat-out refusing to consider if aerosol transmission is important, which leaves people unprotected. So we feel it’s our duty to communicate directly with the public.

How are people using it?

We’ve advertised the document as much as possible through Twitter, emails, and asking journalists to help. That’s how most members of the public see it. There are always more than 100 people looking at it whenever I check, so we know a lot of people are reading it. And people have said it’s very useful. A lot of doctors have said it’s a good resource. And Google Translate means it can be automatically translated it into any language. Every time I give an interview in a new country, people are shocked transmission is mostly through aerosols.

Why did you make this document instead of going down the traditional science publishing route?

Science publishing is very slow. For the scale of the pandemic, people need information today. And publishers can be cryptic. They all have their own rules. In reality, you can only publish things that have not been published before, so it’s not a good way to answer questions from the public. And crucially, it needed to be updateable so we can answer people’s questions as they come. In a journal, it would be frozen.

What have been your main frustrations with the response to the evidence around airborne transmission?

Ever since we wrote that letter, signed by 239 scientists, I have been waiting for the landslide. The evidence is now simply overwhelming that the virus is spread through aerosols. The idea it’s mainly droplets is a myth. It’s an error from 1910 made by Charles Chapin, who wrote a book called The Sources and Modes of Infection. In that book, he associated the risk of infection with droplets. He said, admitting later it had been without evidence, that aerosol transmission is almost impossible, and anyone who says otherwise has to prove it. And that has become dogma ever since. It’s almost a superstition. To this day it’s still what the CDC says.

I’m still waiting for that landslide, where suddenly everyone moves and there’s a huge change. But it hasn’t happened yet. Germany has started saying that good ventilation is the cheapest and best method to reduce the spread of the virus—and that only makes sense if you think it’s mostly spread by aerosols, not droplets or surfaces. The CDC published some guidelines which were confusing, which said inhalation is the main way it spreads—and that means aerosols, as only they can be inhaled—so they were admitting aerosols were the main mode of transmission. Then they took it down. We don’t know if it’s because of politics or dogmatic scientists who refuse to let go of droplets.

Aerosol transmission is the main way this virus spreads: the only question if it’s 70%, 80%, or 90%. Ballistic droplets are a negligible way to spread the virus. They only spread if someone coughs or sneezes on you. They drop to the ground, whereas aerosols linger. If you look at superspreading events, for example the Washington choir case, it is impossible they are being spread by droplets. For 52 people to get infected, it has to be by aerosols. If droplets were important, it would matter less if you are inside or outside, and you’d expect transmission to happen a lot more outdoors. But if you go outside, transmission drops tremendously. The evidence is clear. It’s scandalous and absurd these agencies refuse to give correct guidance.

What are the most important parts of the document to understand for personal safety?

The thing people need to understand is aerosol transmission is like everyone breathing out cigarette smoke, and you want to breathe in as little of others’ as possible. Everyone you are around, imagine they are breathing smoke, and try to avoid it. It’s not good enough to just give people guidelines; you need to explain the actual science behind it, too.

The second most important thing is the recommendations section—how to interpret the science for any given situation. Avoid anything that involves breathing in a lot of other people’s breath. Do things outdoors. But the most important things are free. Wear the mask you already have when you are inside public spaces, and open a window. If we did those, transmission would go down dramatically. Things like ventilation and air filtering matter, but the main things we can do cost nothing.

And finally, perhaps not for the general public but for people who want to understand how we got here—look at the history, in section 1.3 and 1.4 of the document. It is critical, and it explains why the WHO and CDC are not budging. I wonder what percentage of the global population we could reach with our advice. We’ve reached millions, but it’s still a tiny fraction. And if the CDC, WHO, and local health agencies don’t change their guidance, it really defeats the purpose. It makes me so angry.

Read more

Elections are a technology. I don’t mean just that they rely on technology, although cybersecurity, voter data, misinformation, and online advertising are all central to how today’s elections are fought. I mean elections are themselves are a technology—an essential mechanism in the running of a healthy society. Elections enable power to alternate between different factions without civil war; they limit mismanagement and corruption and tyranny; and they provide for a constant flow of new ideas about how best to run the country.

The central component of this technology, other than things like ballot boxes and voter rolls, is trust. If voters don’t trust the election, it fails at its only job, which is to produce a government that is widely accepted as legitimate. And most Americans, right now, do not trust the upcoming presidential election. 

In a Yahoo News/YouGov poll in September, only 22% of Americans thought the election would be “free and fair.” Another 32% said they weren’t sure, and 46% said it would not be. Fully half of Donald Trump’s supporters and 37% of Joe Biden’s fell into the “not free and fair” camp.

Trump is squarely responsible for this. His repeated claims about mass mail-in ballot fraud and other voting irregularities, while absolutely false, explain the high level of distrust in the vote among his own supporters. His attacks on the postal service and his repeated refusals to say whether he’ll accept the election result alarm Biden voters. The hack-prone paperless voting machines still used in some US states and the lingering specter of Russian interference don’t help either. 

The central component of an election is trust. If voters don’t trust the election, it fails at its only job. And most Americans, right now, do not trust the upcoming presidential election. 

Since Democrats are expected to vote by mail at about twice the rate of Republicans, pundits expect that early numbers on Election Day will favor Trump, followed by a large “blue shift” toward Biden in subsequent days as mail-in ballots are counted. The president and his supporters will cast doubt on the results and seek to have some of these votes thrown out by the courts. 

This will set the stage for extended legal wrangling. More than 300 lawsuits are already pending (many brought by Democrats) over voting rules and restrictions that states have imposed in the wake of covid-19. A number of scenarios have described how these fights could delay the result for weeks and possibly end in both Trump and Biden making legally plausible claims to the Oval Office, which the Supreme Court would need to adjudicate.

None of this means Trump cannot win fairly. Even with Biden’s lead in the polls, there are still a number of scenarios in which he does not win the presidency. A (largely) clean Trump victory is entirely possible, though as in 2016 it will almost certainly involve a big disconnect between the popular vote and the Electoral College result. Once again, though, it’s the legitimacy of the result in the eyes of voters that is at stake and that Trump is ferociously undermining. This is bad for America and the whole world, whichever man wins.

All of this is why MIT Technology Review is launching the Outcome, a pop-up newsletter focused on the security and integrity of the election. It will cover topics such as misinformation, voting machines, and cybersecurity, but above all it will ask the same questions of the election that we ask of every technology: Is it working as intended? How are power and money shaping it? How is it being used and misused? What are its strong and weak points? Is it, ultimately, safe?

The Outcome will come to your inbox several days a week, and we expect to keep it running it past Election Day, at least until there’s a result. The lead writer is Patrick Howell O’Neill, our senior editor for cybersecurity, but many of our staff across the newsroom will weigh in. 

We’d love to hear from you, whether it’s about a fight over the placement of ballot drop boxes in your electoral district, a heartwarming story about volunteers helping people vote safely, or some surprising piece of political advertising you came across in your Facebook feed. You can find us on Twitter, Facebook and all the usual places, or you can sign up here to get the Outcome and join the conversation about how to make the election safe again.

Read more

Want to create amazing visuals on Instagram? Wondering how to develop a recognizable Instagram style without needing a design background? To explore how to improve your design on Instagram, I interview Kat Coroy on the Social Media Marketing Podcast. Kat is a designer who teaches small business owners to look amazing on Instagram. She creates […]

The post Instagram Visual Design: How to Improve Your Branding on Instagram appeared first on Social Media Examiner | Social Media Marketing.

Read more
1 2,715 2,716 2,717 2,718 2,719 2,723